| Literature DB >> 27608420 |
Iichiro Okabe1, Takeshi Kikuchi1, Makio Mogi2, Hiroaki Takeda1, Makoto Aino1, Yosuke Kamiya1, Takeki Fujimura1, Hisashi Goto1, Kosuke Okada1, Yoshiaki Hasegawa3, Toshihide Noguchi1, Akio Mitani1.
Abstract
Interleukin-15 (IL-15), a cytokine secreted by several cell types, has important physiological roles in the activity, proliferation, and viability of immune cells. It has both chemoattractant and proinflammatory properties, and may promote bone destruction. A previous study has shown that IL-15 alone exerts no effect on osteoclastogenesis. Therefore, the current study addressed the synergistic effect of IL-15 on osteoclast formation using RAW264.7 (RAW) cells by co-stimulation with receptor activator of nuclear factor (NF)-κB ligand (RANKL) that has a major role in osteoclastogenesis involving the pathogenesis of rheumatoid arthritis and periodontal disease. Co-stimulation of RAW cells by IL-15 and RANKL significantly increased the gene expression of osteoclast differentiation and osteoclastogenesis markers compared with stimulation by RANKL or IL-15 independently as evaluated by tartrate-resistant acid phosphate-positive cell numbers, the fusion index, a pit formation assay with Alizarin red staining (calcification estimation), and quantitative polymerase chain reaction. Phosphorylation of extracellular signal-regulated kinase (ERK), c-jun N-terminal kinase, p38 mitogen-activated protein kinase, and NF-κB was significantly increased by RANKL and IL-15 (P < 0.05) compared with RANKL alone. In addition, these differentiation activities induced by RANKL and IL-15 were comparatively suppressed by inhibition of ERK, suggesting that this synergistic effect on osteoclastogenesis is mainly mediated by ERK. Taken together, our results demonstrate that IL-15 and RANKL induce osteoclastogenesis synergistically, and IL-15 might play a novel and major role in destructive inflammatory bone diseases. J. Cell. Biochem. 118: 739-747, 2017.Entities:
Keywords: INFLAMMATORY BONE DESTRUCTION; INTERLEUKIN-15; OSTEOIMMUNOLOGY
Mesh:
Substances:
Year: 2016 PMID: 27608420 DOI: 10.1002/jcb.25726
Source DB: PubMed Journal: J Cell Biochem ISSN: 0730-2312 Impact factor: 4.429